TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

Transforming growth factor-β (TGF-β) signaling regulates multiple physiological processes, such as cell proliferation, differentiation, immune homeostasis, and wound healing. Besides, TGF-β plays a vital role in diseases, including cancer. Accumulating evidence indicates that TGF-β controls the comp...

Full description

Bibliographic Details
Main Authors:	Ming Yi, Tianye Li, Mengke Niu, Yuze Wu, Zhenyu Zhao, Kongming Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Immunology
Subjects:	cancer biotherapy cancer immunotherapy tumor microenvironment TGF-β PD-1 PD-L1
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1061394/full

Similar Items

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
by: Ming Yi, et al.
Published: (2021-02-01)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
by: Mengke Niu, et al.
Published: (2023-08-01)

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01)

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
by: Ming Yi, et al.
Published: (2022-10-01)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
by: Tianye Li, et al.
Published: (2023-07-01)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
by: Mengke Niu, et al.
Published: (2022-03-01)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
by: Mengke Niu, et al.
Published: (2021-03-01)

Regulation of PD-L1 expression in the tumor microenvironment
by: Ming Yi, et al.
Published: (2021-01-01)

Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials
by: Linwei Li, et al.
Published: (2022-07-01)

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
by: Masaki Terabe, et al.
Published: (2017-05-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
by: Zhitao Li, et al.
Published: (2021-11-01)

The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 Pathways
by: Michael J. Birrer, et al.
Published: (2022-02-01)

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
by: Ming Yi, et al.
Published: (2021-09-01)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020-05-01)

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
by: Rita Greco, et al.
Published: (2020-01-01)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
by: Peng Ding, et al.
Published: (2023-05-01)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
by: Laure Chardin, et al.
Published: (2021-12-01)

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
by: Enrico Munari, et al.
Published: (2021-05-01)

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
by: Jue Zhu, et al.
Published: (2021-08-01)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
by: Mengling Wu, et al.
Published: (2022-03-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
by: Zhang-Wei Hu, et al.
Published: (2022-08-01)

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
by: James L. Gulley, et al.
Published: (2022-06-01)

Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
by: Yuegang Li, et al.
Published: (2022-10-01)

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
by: Marije Baas, et al.
Published: (2016-01-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
by: Seri Jeong, et al.
Published: (2021-10-01)

Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy
by: Zhen-Hua Wu, et al.
Published: (2022-10-01)

A novel PD-1/PD-L1 pathway molecular typing-related signature for predicting prognosis and the tumor microenvironment in breast cancer
by: Yuxin Man, et al.
Published: (2023-05-01)

Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
by: Keyu Yuan, et al.
Published: (2022-09-01)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
by: Liping Pei, et al.
Published: (2023-02-01)

Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction
by: Fengling Wang, et al.
Published: (2023-02-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
by: Junjie Liu, et al.
Published: (2022-09-01)

Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis
by: Racheal Louise Johnson, et al.
Published: (2023-09-01)

A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects
by: Wei-Yun Lai, et al.
Published: (2016-01-01)

The PD1: PD-L1/2 pathway from discovery to clinical implementation
by: Kankana Bardhan, et al.
Published: (2016-12-01)